HLB Panagene Co., Ltd. (KOSDAQ:046210)

South Korea · Delayed Price · Currency is KRW

1,110.00

-371.00 (-25.05%)

At close: Jul 10, 2026

-44.22% (1Y)

Market Cap	50.54B -48.2%
Revenue (ttm)	14.64B +9.8%
Net Income	-3.62B
EPS	-79.64
Shares Out	45.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,975,887
Open	1,057.00
Previous Close	1,481.00
Day's Range	1,037.00 - 1,153.00
52-Week Range	1,110.00 - 2,940.00
Beta	-0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About HLB Panagene

HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 1976

Employees 82

Stock Exchange KOSDAQ

Ticker Symbol 046210

Full Company Profile

Financial Performance

In 2025, HLB Panagene's revenue was 15.05 billion, an increase of 14.04% compared to the previous year's 13.20 billion. Losses were -3.13 billion, 60.8% more than in 2024.

Financial Statements